← back to search

Pierre Quartier

Rockefeller University · US
Area of research
Hematology · Speech and Hearing
Research interest
Research focused on Immunology and Disease, with related work in Juvenile, Immunodeficiency, Prednisone. Notable publications include 'Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency', 'Detection of interferon alpha protein reveals differential levels and cellular sources in disease', and 'Treating juvenile idiopathic arthritis to target: recommendations of an international task force'.
h-index
citations
2,966
works
31
NIH funding
primary concept
email

Recent publications

Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis
Pediatric Rheumatology 2025cited by 3position: middledoi
The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset Still’s disease
EULAR Rheumatology Open 2025cited by 1position: middledoi
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease
Annals of the Rheumatic Diseases 2024cited by 151position: middledoi
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project
Lara D. Veeken 2024cited by 30position: middledoi
Individuals with <i>JAK1</i> variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis
The Journal of Experimental Medicine 2024cited by 22position: middledoi
Helper T cell immunity in humans with inherited CD4 deficiency
The Journal of Experimental Medicine 2024cited by 14position: middledoi
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry
Lara D. Veeken 2024cited by 14position: middledoi
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score
Lara D. Veeken 2024cited by 3position: middledoi
mTORC1 links pathology in experimental models of Still’s disease and macrophage activation syndrome
Nature Communications 2022cited by 39position: middledoi
Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis
The Journal of Rheumatology 2020cited by 14position: middledoi
Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling
Lara D. Veeken 2019cited by 38position: middledoi
Treating juvenile idiopathic arthritis to target: recommendations of an international task force
Annals of the Rheumatic Diseases 2018cited by 349position: middledoi
Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
PubMed 2018cited by 60position: middle
The European network for care of children with paediatric rheumatic diseases: care across borders
Lara D. Veeken 2018cited by 25position: middledoi
Detection of interferon alpha protein reveals differential levels and cellular sources in disease
The Journal of Experimental Medicine 2017cited by 374position: middledoi
ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis
Annals of the Rheumatic Diseases 2017cited by 173position: firstdoi
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus
Autoimmunity Reviews 2017cited by 37position: middledoi
THU0641 The disease burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international health related quality of life survey and retrospective chart review
Annals of the Rheumatic Diseases 2017cited by 1position: middledoi
The Impact Of Systemic Juvenile Idiopathic Arthritis (SJIA) On A Caregiver’s Productivity And The Child’s Schooling
Value in Health 2017cited by 0position: middledoi
Health Related Quality Of Life For Systemic Juvenile Idiopathic Arthritis (SJIA) Patients And Caregivers On Biologic Therapy, From A Caregiver’s Perspective
Value in Health 2017cited by 0position: middledoi
Compliance And Treatment Satisfaction With Biological Treatments For Systemic Juvenile Idiopathic Arthritis (SJIA)
Value in Health 2017cited by 0position: middledoi
Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease
Journal of Clinical Immunology 2016cited by 203position: middledoi
Development of the autoinflammatory disease damage index (ADDI)
Annals of the Rheumatic Diseases 2016cited by 76position: middledoi
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
The Lancet 2015cited by 228position: middledoi
Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ
Lara D. Veeken 2015cited by 144position: middledoi
Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind
Current Opinion in Immunology 2015cited by 76position: middledoi
Brief Report: Childhood‐Onset Systemic Necrotizing Vasculitides: Long‐Term Data From the French Vasculitis Study Group Registry
Arthritis & Rheumatology 2015cited by 59position: middledoi
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent
RMD Open 2015cited by 50position: lastdoi
Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry
Annals of the Rheumatic Diseases 2014cited by 241position: middledoi
Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency
Nature Immunology 2012cited by 465position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ivan Foeldvari · Hospital for Sick Children5 papers (2017–2025)Brigitte Bader‐Meunier · KU Leuven5 papers (2012–2016)J Gregson · Novartis (Switzerland)4 papers (2017–2017)Athimalaipet V Ramanan · University Hospital Heidelberg4 papers (2017–2017)Michal Cidon · Palo Alto University4 papers (2017–2017)Susan Shenoi · Seattle Children's Hospital4 papers (2017–2017)Gerd Horneff · University of Alabama at Birmingham4 papers (2017–2017) · 4 papers (2017–2017)Yukiko Kimura · Nationwide Children's Hospital4 papers (2017–2017)Andrew Zeft · University of Missouri–Kansas City4 papers (2017–2017)Carine Wouters · KU Leuven3 papers (2012–2015) · 3 papers (2017–2017)S.J. McKenna · California University of Pennsylvania3 papers (2017–2017)Kathleen G. Lomax · AbbVie (United States)2 papers (2017–2017) · 2 papers (2017–2017)Isabelle Melki · Amgen (United States)2 papers (2015–2016) · 2 papers (2017–2017)Isabelle Koné‐Paut · University of Tübingen2 papers (2014–2017)Eugen Feist · Helios Klinikum Emil von Behring2 papers (2018–2025)Alexandre Bélot · Université Claude Bernard Lyon 12 papers (2016–2017)